Isotope Technologies Munich (ITM) plans to present dosimetry data from its Phase 3 COMPETE trial at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
The company will share results that describe the use of single-time–point dosimetry of ITM-11 (Lutetium-177 [Lu-177] edotreotide), its investigational somatostatin receptor-targeted radiotherapeutic. The COMPETE trial compared ITM-11 to everolimus in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), meeting its primary endpoint of improved progression-free survival, ITM said.
Lu-177 edotreotide is under review by the U.S. Food and Drug Administration (FDA) and has not been approved for any indication.
Check out AuntMinnie’s full coverage of SNMMI 2026 on our ShowCast.
![(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/mei.XUQJWkpAJI.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
![RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/screenshot-2026-05-27-205827.278Ys6PYU3.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
